Deepankar Sharma, MD
Pulmonary Disease · Columbus, INNPI 1285947226
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,725 of the $13,435 with a category attached, or 79.8%. Merit Medical Systems Inc accounts for 82.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $6,323 and has fallen 88.4% since, to $732 in 2025.
Across 25 payments — averaging $537.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merit Medical Systems Inc$11K
- Pulmonx Corporation$2K
- Intuitive Surgical$854
- Olympus Corporation Of The Americas$26
- Insmed, Inc.$19
- Amgen$18
What the payments were for
- Consulting fees$10,72580%
- Travel & lodging$2,11516%
- Food & beverage$3032%
- Education$1121%
- Gifts$1801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merit Medical Systems Inc | 11 | $11,012 |
| Pulmonx Corporation | 4 | $1,506 |
| Intuitive Surgical | 7 | $854 |
| Olympus Corporation Of The Americas | 1 | $26 |
| Insmed, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,435 in reported general payments places this provider in the 80th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $59,970 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $33,840 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $31,308 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $24,356 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $18,231 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $6,575 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $6,243 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,035 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $4,320 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,120 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 109 | $3,169 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,365 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,327 |
| Montelukast Sodium | 36 | $461 |
| Prednisone | 42 | $196 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Columbus
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.